Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Seamlessly bridge your LNP discovery journey from RUO to bulk GLP-tox and GMP excipient-grade material.
Explore CGMP Lipid ServicesLipid 14 is an ionizable cationic amino lipid that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing lipid 14 and encapsulating mRNA encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein receptor-binding domain (RBD), also known as the surface glycoprotein RBD, increase anti-RBD antibody levels in mice, as well as increase the number of isolated mouse splenocytes secreting IFN-γ and IL-2, but not IL-4 or IL-10, when incubated with the SARS-CoV-2 spike glycoprotein. LNPs containing lipid 14 and encapsulating mRNA encoding the bacterial Caf1 (F1) capsule antigen from Y. pestis, the bacteria that causes bubonic plague, induces anti-F1 cellular and humoral responses and protects against lethal Y. pestis infection in mice.2
WARNING This product is not for human or veterinary use.
1. Design of SARS-
2. A single-